Abstract
SET (SE translocation, SET) is an evolutionarily conserved gene broadly expressed in various human tissues, especially in the gonadal and neural system. As a multitasking protein, SET is involved in essential cell processes such as histone modification, chromatin remodeling, DNA repair, gene transcription, and androgen synthesis. Recent studies showed that SET is overexpressed in breast cancers, ovary cancers and a variety of other malignancies. The strong correlation between SET expression levels and survival of ovarian cancer patients, and SET-mediated activation of androgen synthesis, strongly indicated that this factor may play a significant role in gynecologic cancers. Here, we summarized data pertaining to the pathological implications of SET in tumorigenesis and cancer progression. We analyzed how SET, through the PP2A-dependent and PP2A-independent pathways, may regulate different cell functions. Potential interactions among these pathways and future studies on SET’s oncogenic activities are also discussed.
Keywords: SET, PP2A, I2PP2A, INHAT, gynecologic cancer, steroid hormone, histone chaperone.
Current Drug Targets
Title:Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Volume: 18 Issue: 10
Author(s): Shi-wen Jiang, Siliang Xu, Haibin Chen, Jiayin Liu*Ping Duan
Affiliation:
- The State Key Laboratory of Reproductive Medicine, Center of Clinical Reproductive Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Nanjing 210029,China
Keywords: SET, PP2A, I2PP2A, INHAT, gynecologic cancer, steroid hormone, histone chaperone.
Abstract: SET (SE translocation, SET) is an evolutionarily conserved gene broadly expressed in various human tissues, especially in the gonadal and neural system. As a multitasking protein, SET is involved in essential cell processes such as histone modification, chromatin remodeling, DNA repair, gene transcription, and androgen synthesis. Recent studies showed that SET is overexpressed in breast cancers, ovary cancers and a variety of other malignancies. The strong correlation between SET expression levels and survival of ovarian cancer patients, and SET-mediated activation of androgen synthesis, strongly indicated that this factor may play a significant role in gynecologic cancers. Here, we summarized data pertaining to the pathological implications of SET in tumorigenesis and cancer progression. We analyzed how SET, through the PP2A-dependent and PP2A-independent pathways, may regulate different cell functions. Potential interactions among these pathways and future studies on SET’s oncogenic activities are also discussed.
Export Options
About this article
Cite this article as:
Jiang Shi-wen , Xu Siliang, Chen Haibin, Liu Jiayin *, Duan Ping, Oncogenic Role of SET/I2PP2A for Gynecologic Cancers, Current Drug Targets 2017; 18 (10) . https://dx.doi.org/10.2174/1389450118666170328114506
DOI https://dx.doi.org/10.2174/1389450118666170328114506 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Liprins in the Regulation of Tumor Cell Motility and Invasion
Current Cancer Drug Targets Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy
Current Cancer Drug Targets Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Signal Transduction of Radiation and/or Hyperthermic Cancer Therapies
Current Signal Transduction Therapy Phosphonate Analogues of 1α, 25 Dihydroxyvitamin D<sub>3</sub> are Promising Candidates for Antitumoural Therapies
Current Topics in Medicinal Chemistry Expression of NRP-1 and NRP-2 in Endometrial Cancer
Current Pharmaceutical Biotechnology Application of Nanoparticles for Efficient Delivery of Quercetin in Cancer Cells
Current Medicinal Chemistry Effectiveness <i>In Vivo</i> and <i>In Vitro</i> of Polymeric Nanoparticles as a Drug Release System in the Treatment of Leishmaniasis
Current Medicinal Chemistry Therapeutic Potential of Naturally Occurring Lignans as Anticancer Agents
Current Topics in Medicinal Chemistry The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer
Current Radiopharmaceuticals Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?
Current Pharmaceutical Biotechnology Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry The Cytoplasmic Rhodopsin-Protein Interface: Potential for Drug Discovery
Current Drug Targets Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Tertiary Lymphoid Structures Gene Signature Predicts Prognosis and Immune Infiltration Analysis in Head and Neck Squamous Cell Carcinoma
Current Genomics Apoptosis Following Photodynamic Tumor Therapy: Induction, Mechanisms and Detection
Current Pharmaceutical Design